SCHEMBL29920835

SCHEMBL29920835

CC1COc2ccccc2C1(O)CS(=O)(=O)NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
AKR1B1 P15121 2/20 0.39
ACACB O00763 1/20 0.34
STS P08842 1/20 0.34
PDK2 Q15119 1/20 0.34
EPHX2 P34913 1/20 0.33
SSTR4 P31391 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KCNA3 P22001 1/20 0.32
LTB4R Q15722 1/20 0.32
LTB4R2 Q9NPC1 1/20 0.32
KDM1A O60341 1/20 0.32
MAOB P27338 1/20 0.32
GAA P10253 1/20 0.32
IDO1 P14902 1/20 0.31
ABCB1 P08183 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29920729 0.85 AKR1B1 (0.43) CA12CA1CA7CA14AKR1B1
SCHEMBL29920578 0.77 AKR1B1 (0.55) CA12CA1CA7CA14AKR1B1
SCHEMBL29920345 0.75 AKR1B1 (0.37) AKR1B1
SCHEMBL29920385 0.67 MAP3K14 (0.39) CA12CA1CA7CA14AKR1B1
SCHEMBL29920625 0.66 MAP3K14 (0.54) CA12CA1CA7CA14AKR1B1
SCHEMBL29920603 0.66 MAP3K14 (0.38) CA12CA1CA7CA14AKR1B1
SCHEMBL29920606 0.65 AKR1B1 (0.40) CA12CA1CA7CA14AKR1B1
SCHEMBL5322132 0.64 KDM1A (0.44) EPHX2KMT2AL3MBTL1KCNA3KDM1A
SCHEMBL30799332 0.64 GAA (0.52) EPHX2SSTR4KMT2AL3MBTL1KCNA3
SCHEMBL21542268 0.64 KDM1A (0.44) EPHX2SSTR4KMT2AL3MBTL1LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182436-A1 SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2024-06-06 US disclosed
WO-2022217248-A1 SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182436-A1 SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ARSA, SNCA, F12 CA12 628/4885CA1 311/4885CA7 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.